| |NOVEMBER 20249LATEST PENICILLIN PLANT BOASTS PRODUCTION CAPACITY OF 15,000MTEMCURE PHARMA ESTABLISHES DEDICATED SUBSIDIARY FOR DERMATOLOGYLyfius Pharma, a unit of Aurobindo Pharma, on Tuesday said Prime Minister Narendra Modi has inaugurated its Penicillin-G plant at Kakinada, Andhra Pradesh. The facility with an annual production capacity of 15,000 metric tonnes (MT) was virtually inaugurated by Prime Minister Narendra Modi in the presence of Union Health Minister Jagat Prakash Nadda and other dignitaries.The facility represents a strategic investment of Rs 2,500 crore under the government's PLI Scheme and exemplifies how private sector participation can significantly contribute to national growth, drive innovation, and enhance healthcare security, Lyfisu Pharma said in a regulatory filing.The PLI scheme for the pharmaceutical sector aims to strengthen domestic manufacturing capabilities in critical KSMs, DIs, and APIs."The launch of our PenG facility is a significant milestone in our efforts to enhance local production and reduce import dependency for critical pharmaceutical ingredients," Lyfius Pharma Director MV Rama Krishna said.The investment underscores the company's commitment to support the government's vision of 'Atmanirbhar Bharat', establishing India as a global pharmaceutical manufacturing hub, he added. POEmcure Pharmaceuticals Limited has announced the formation of a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited, which will focus exclusively on dermatology.To be spearheaded by industry veteran G. Sathya Narayanan, Emcutix will enhance Emcure's portfolio with a wide range of innovative solutions for skin health, addressing both therapeutic and aesthetic needs.Mr. Narayanan brings with him over three decades of extensive experience in the dermatology sector, with his last stint as the Managing Director of Galderma for South Asia (including India).His career includes building some of the most iconic brands in prescription, consumer, and aesthetic dermatology.As a part of the new initiative, Emcure's existing dermatology business will also operate under Emcutix.With a dedicated team, the focus will be on building a differentiated product portfolio including first-time launches designed to fulfil the unmet needs of the Indian dermatology market.Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals said, "The dermatology market in India, is experiencing a significant surge in both value and unit consumption. Emcure is well-positioned to cater to the unmet needs of the Indian market.""With a dedicated entity, Emcure aims to concentrate on developing and introducing both prescription and consumer dermatology solutions," he said.Sathya Narayanan, CEO, Emcutix said, "Emcutix represents a unique opportunity with derma care solutions for healthcare professionals, patients and consumers by developing a differentiated dermatology portfolio. Building on Emcure's legacy of innovation, I look forward to building a portfolio of products that will make a meaningful difference in skin health in India." PO
< Page 8 | Page 10 >